Render Target: SSR
Render Timestamp: 2025-02-06T17:37:18.660Z
Commit: 1bba917eefc12d62e72a522121e2774ffbd0ee36
XML generation date: 2024-11-13 16:01:06.795
Product last modified at: 2025-01-30T15:15:09.084Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Antibody Sampler Kit
PDP - Template ID: *******4a3ef3a

Protein Folding and Stability Antibody Sampler Kit #4889

    Product Information

    Product Description

    This sampler kit provides an economical means to investigate protein folding and stability. The kit contains primary and secondary antibodies to perform two Western blots with each antibody.

    Background

    The small regulatory protein ubiquitin is often covalently linked to many cellular proteins, labeling these targeted proteins for proteasome-mediated degradation. Ubiquitin is first activated by forming a thiolester complex with the E1 activation component. Activated ubiquitin is subsequently transferred to the ubiquitin-carrier protein E2, and then to an E3 ubiquitin ligase for final delivery to the ε-NH2 of the target protein lysine residue (1). The ubiquitin-proteasome pathway has been implicated in a wide range of both normal biological processes and diseases (2,3).
    The ubiquitin-like protein family contains three small ubiquitin-related modifier proteins (SUMO-1, -2 and -3), neural precursor cell-expressed developmentally down-regulated protein 8 (NEDD8) and interferon-stimulated 15 kDa protein (ISG15) (4-6). Their covalent attachment to target proteins is a reversible, multi-step process that is analogous to protein ubiquitination. Mature molecules are linked to the activating enzyme E1, conjugated to E2 and ligated to the target proteins by E3 (7-10). Ubiquitin is the predominant regulator for the degradation of a wide range of target proteins (8) while SUMO, NEDD8 and ISG15 modify a limited set of substrates to regulate various other biological processes (4, 11-18).
    During ubiquitination, the combinatorial interaction of different E2 and E3 proteins produces variable substrate specificity (4). UBC3 and UBC3B are E2 ubiquitin-carrier proteins (19, 20). The SCF (Skp1/CUL1/F-box) E3 ubiquitin ligase protein complex is composed of three protein components, including the S phase kinase associated protein 1 (Skp1), Cullin homolog 1 (CUL1) and the Skp2 F-box protein (21-23).
    1. Ciechanover, A. (1998) EMBO J. 17, 7151-7160.
    2. Bernardi, R. et al. (2000) Oncogene 19, 2447-2454.
    3. Jesenberger, V. and Jentsch, S. (2002) Nat. Rev. Mol. Cell Biol. 3, 112-121.
    4. Schwartz, D.C. and Hochstrasser, M. (2003) Trends Biochem. Sci. 28, 321-328.
    5. Chiba, T. and Tanaka, K. (2004) Curr. Protein Pept. Sci. 5, 177-184.
    6. Ritchie, K.J. and Zhang, D.E. (2004) Semin. Cell Dev. Biol. 15, 237-246.
    7. Kim, K.I. et al. (2002) J. Cell Physiol. 191, 257-268.
    8. Osaka, F. et al. (1998) Genes Dev. 12, 2263-2268.
    9. Loeb, K.R. and Haas, A.L. (1992) J. Biol. Chem. 267, 7806-7813.
    10. Zhao, C. et al. (2005) Proc. Natl. Acad. Sci. USA 102, 10200-10205.
    11. Matunis, M.J. et al. (1996) J. Cell Biol. 135, 1457-1470.
    12. Duprez, E. et al. (1999) J. Cell Sci. 112 ( Pt 3), 381-393.
    13. Gostissa, M. et al. (1999) EMBO J. 18, 6462-6471.
    14. Rodriguez, M.S. et al. (1999) EMBO J. 18, 6455-6461.
    15. Desterro, J.M. et al. (1998) Mol. Cell 2, 233-239.
    16. Stickle, N.H. et al. (2004) Mol. Cell. Biol. 24, 3251-3261.
    17. Xirodimas, D.P. et al. (2004) Cell 118, 83-97.
    18. Hamerman, J.A. et al. (2002) J. Immunol. 168, 2415-2423.
    19. Semplici, F. et al. (2002) Oncogene 21, 3978-3987.
    20. Pagano, M. et al. (1995) Science 269, 682-685.
    21. Yu, Z.K. et al. (1998) Proc. Natl. Acad. Sci. USA 95, 11324-11329.
    22. Pagano, M. (2004) Mol. Cell 14, 414-416.
    23. Reed, S.I. (2003) Nat. Rev. Mol. Cell Biol. 4, 855-864.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.